Acellular Dermal Matrix Performance Compared with Latissimus Dorsi Myocutaneous Flap in Expander-Based Breast Reconstruction

James Randall Patrinely, Jr, BA*  
Angel Farinas, MD†  
Bader Al-Majed, MD‡  
Antonio Jorge Forte, MD, PhD§  
Sarvam TerKonda, MD¶  
Galen Perdikis, MD†

**Background:** Latissimus dorsi myocutaneous flap (LDMF) with tissue expander provides excellent results in breast reconstruction. Acellular dermal matrix (ADM) has been used in expander-based reconstruction (EBR) with good results. This study assesses how ADM compares to LDMF in EBR.

**Methods:** The cohorts comprised 124 patients (218 breasts) who had EBR using ADM between 2006 and 2012, and 242 patients (266 breasts) who had EBR using LDMF between 1994 and 2012. Postoperative complications, reoperations, Breast-Q scores, and objectively assessed aesthetic outcomes were compared.

**Results:** Median age was 55 years for both ADM (range 23–84) and LDMF (range 26–88) groups. No statistically significant differences were noted between the groups in the rates of major postoperative complications ($P > 0.3$). Forty-nine of the 218 (22.5%) in the ADM group and 67 of 266 (25.2%) in the LDMF group had a total of 63 and 84 reoperations, respectively ($P = 0.52$), with no significant differences in the reoperations rate ($P > 0.3$). No significant differences were observed in the Breast-Q scores. Some categorical differences were noted in the aesthetic outcomes; however, the difference between the overall outcomes was not significant ($P = 0.54$).

**Conclusion:** Our study revealed no statistically significant differences in the complications or reoperation rates, patient satisfaction, or overall aesthetic outcomes when comparing the use of ADM to LDMF in EBR. In conclusion, this study supports the hypothesis that ADM performs as well as LDMF in EBR. (Plast Reconstr Surg Glob Open 2019;7:e2414; doi: 10.1097/GOX.0000000000002414; Published online 30 September 2019.)

**INTRODUCTION**

Secondary only to lung cancer, breast cancer is the most common cause of cancer-related mortality in females and accounts for 500,000 deaths worldwide annually.1,2 It affects ~1 in 8 women, and with 1,600,000 new cases, each year has an increasing prevalence. Mastectomy remains one of the primary treatments, and plastic surgeons play a crucial role in reconstruction.3 With approximately 100,000 breast reconstruction procedures performed annually in the United States, identifying the safest, most efficient, and cosmetically superior technique is crucial.4

The popularity of breast reconstruction using autologous tissue emerged in the late 1980s after the public acceptance of silicone breast implants deteriorated due to inflated claims of their risks.5,6 During this time, reconstruction using the latissimus dorsi myocutaneous flap (LDMF) increased as a viable option.7–9 LDMF was originally indicated for patients with a history of significant radiotherapy or complex mastectomies.10,11 Currently, LDMF has been shown to be particularly useful in unilateral reconstruction and...
in those patients who had radiation with acceptably low capsular contracture rates (6%–12%).13,16

More recently, reconstruction using allogenic tissue with acellular dermal matrix (ADM) has become increasingly popular. ADM was introduced in 2001 for revisional aesthetic surgery and was first used for expander-based reconstruction (EBR) in 2007.17,18 EBR using ADM has had variable, but increasingly reliable reported surgical and aesthetic outcomes.19,20

To date, no large study has directly compared LDMF with ADM in patients undergoing EBR. This study evaluates and compares the incidence of complications, aesthetic quality, and patient satisfaction between EBR using LDMF and ADM.

METHODS

After obtaining study approval by the Institutional Review Board at Mayo Clinic, we conducted a retrospective review of patients who received EBR using ADM between June 2006 and December 2012, and patients who had EBR using LDMF between April 1994 and December 2012. Patients were excluded if they had failed a previous breast reconstruction or if they were not breast cancer victims. Postoperative complications were tracked and included breast seroma, capsular contracture (grade 3 or 4), prosthesis exposure, prosthesis rupture, and aesthetic considerations (malposition, symmastia, size). The number of reoperations and scar revisions were also recorded. Patient satisfaction was assessed using the Breast-Q preoperatively and postoperatively. To measure patient satisfaction, photos of LDMF and ADM patients who completed their second stage of reconstruction were randomly selected and assessed by 3 independent physicians on a 1–10 scale based on the inframammary fold, position, resemblance of a natural breast, visible scarring, and symmetry. A subgroup analysis for each cohort with and without a history of radiation was also conducted to assess differences in complication rates and patient satisfaction. Fisher exact and Wilcoxon rank sum tests were used for statistical analysis.

RESULTS

Our retrospective analysis included 124 patients (218 breasts) with EBR using ADM and 242 patients (266 breasts) with EBR using LDMF. The median age was 55 years (23–84 years for ADM, and 26–88 years for LDMF) (Table 1). There were no statistically significant differences in postoperative complication rates (Table 2). Mastectomy flap necrosis was the most common recorded complication and similar between the groups (ADM: 6.9%, LDMF: 6.4%). The reoperation rate for ADM compared with LDMF was also similar (22.5% versus 25.2%, \(P = 0.52\)). There was no statistically significant difference in Breast-Q scores (Table 3). LDMF displayed significantly better scores in aesthetic subcategories for volume (\(P < 0.01\)), placement (\(P < 0.01\)), and inframammary fold (\(P = 0.02\)), but no significant difference in overall aesthetic appearance (\(P = 0.54\)) (Table 4). The most common indication for reoperation in both groups was aesthetics (malposition, symmastia, size) (Table 5).

Prior history of radiotherapy was significantly higher in the LDMF cohort compared with patients with ADM (42.1% versus 12.8%, \(P < 0.001\)). Of the patients who received LDMF, those with a history of radiotherapy had a significantly higher rate of breast cellulitis (8.0% versus 1.9%, \(P = 0.032\)) and a lower rate of seroma (0.0% versus 4.5%, \(P = 0.044\)) (Table 6). Patients with ADM and prior radiotherapy had a significantly increased risk of capsular contracture compared with ADM patients without radiotherapy (21.4% versus 2.1%, \(P < 0.001\)) (Table 7). There was no significant difference in Breast-Q scores for either LDMF or ADM patients with or without a history of radiotherapy (Table 8–9).

DISCUSSION

In 2016, ~100,000 women had reconstruction after mastectomy in the United States.23 EBR using ADM and LDMF are both common reconstructive methods. The use of ADM was introduced in the early 2000s but has had conflicting reports of postoperative complication rates.24,25,26 Perhaps a more complicated procedure, LDMF is generally regarded as reliable with favorable aesthetic outcomes, low complications rates, and performs well in the face of radiation.12,27

There is little-published data directly comparing outcomes of EBR using ADM or LDMF. The purpose of this study was to analyze the clinical and aesthetic outcomes of these 2 procedures. In 2016, Youssef et al performed a study that prospectively tracked 20 patients, with 12 receiving immediate ADM and 9 delayed LDMF. They found no differences between clinical and patient satisfaction, which is similar to our results. Thus far, we present the most substantial study comparing EBR using LDMF and ADM.

Prior history of radiotherapy was significantly higher in patients with LDMF. Otherwise, there were no differences in demographics or preference for either procedure based on age group. Further, there were no significant differences between the 2 procedures in any of the tracked postoperative complications or reoperation rates. These findings differ from previous literature. In 2010, Chun et al found an increased 4.2- and 5.3-times risk of seroma formation and infection, respectively, when using ADM for breast reconstruction compared with not using ADM. Ho et al also concluded that patients were more likely to develop infections after using ADM for breast reconstruction. Interestingly, the prevalence of infection with ADM in our study was 5.7%, which is comparable to Ho’s meta-analysis. Although the infection rate was not significantly

| Variable | Overall | LDMF | ADM |
|----------|---------|------|-----|
| No. patients | 366 | 242 | 124 |
| No. breasts | 484 | 266 | 218 |
| Radiotherapy (breasts) | 140 | 112 (42.1%) | 28 (12.8%) |
| Median age at first stage, y | 55 (23, 88) | 55 (26, 88) | 55 (23, 84) |
| Follow-up period, mo | 23 (1, 191) | 28 (1, 191) | 18 (1, 76) |
different from LDMF patients in our study, there are a few hypotheses for the higher rate associated with ADM. Prior publications have tried to explain this phenomenon by linking it to the quality of the remaining skin flap. 24,29,31 The compliance of ADM allows it to adjust to a higher initial volume. The high intraoperative filling volumes of tissue expanders result in an augmented stretching of the native breast flap. This can compromise blood supply and lead to necrosis with the development of a secondary infection. 27,31 To prevent this complication, some authors have recommended avoiding aggressive initial overexpansion and using indocyanine green angiography.
intraoperatively to assess the flap viability. Thin, ischemic flaps are also prone to implant extrusion and seroma formation. Another hypothesis postulated that ADM could act as a nidus of infection. LDMF is a versatile reconstructive technique, utilized in immediate, delayed, or salvage reconstruction. Reconstruction with the LDMF previously fell out of popularity due to concerns about high capsular contracture rates when used with an implant, and the parallel development of abdominal-based free flaps. Regarding cosmetic outcomes, LDMF was superior to ADM when considering volume, placement, and inframammary fold. However, the overall aesthetic outcome was not significantly different between the groups. There is conflicting literature on the aesthetic outcomes of LDMF. Some authors have

### Table 5. Reoperation Incidences Based on Type of Surgery (Breasts)

| Variable                              | Overall (n = 484) | LDMF (n = 266) | ADM (n = 218) | Rate (%) | Rate (%) | Rate (%) | P (two-tailed) |
|---------------------------------------|------------------|----------------|---------------|----------|----------|----------|----------------|
| Aesthetic (malposition, symmastia, size) | 30               | 18             | 12            | 6.8      | 5.5      | 0.578    |
| Capsular contracture (grade III/IV)    | 7                | 5              | 2             | 1.9      | 0.9      | 0.466    |
| Exposure of prosthetics               | 15               | 6              | 9             | 2.3      | 4.1      | 0.295    |
| Seroma (breast)                       | 13               | 4              | 2             | 1.5      | 0.9      | 0.695    |
| Hematoma (breast)                     | 9                | 3              | 3             | 1.1      | 1.4      | 1.000    |
| Infection (requiring removal of prosthelic) | 23               | 11             | 12            | 4.1      | 5.5      | 0.524    |
| Necrosis (skin, flap, fat)            | 18               | 10             | 8             | 3.8      | 3.7      | 1.000    |
| Ruptured/leaking prosthetic           | 8                | 6              | 2             | 2.3      | 0.9      | 0.304    |
| Scar/skin revision/resection          | 22               | 10             | 12            | 3.8      | 5.5      | 0.387    |
| Flap loss                             | 1                | 1              | 0             | 0.4      | 0.0      | —        |
| Exploration                           | 1                | 0              | 1             | 0.0      | 0.5      | —        |

### Table 6. LDMF (Breasts) Complications Based on Radiation Therapy

| Variable                              | Without Radiotherapy (n = 154) | Rate (%) | With Radiotherapy (n = 112) | Rate (%) | P (Two-tailed) |
|---------------------------------------|-------------------------------|----------|-------------------------------|----------|----------------|
| Age at first stage, y                 | 57 (33, 88)                   | 51 (26, 78) | —                             | 28.6     | 0.317          |
| Unplanned reoperation                 | 35                            | 22.7     | 32                            | —        | 0.003          |
| Malposition                           | 7                             | 4.5      | 6                             | 5.4      | 0.780          |
| Capsular contracture grade III/IV     | 5                             | 3.2      | 5                             | 3.6      | 1.000          |
| Time of onset of capsular contracture, mo | 13 (6, 39)                | 12 (5, 35) | —                             | 2.7      | 1.000          |
| Ruptured/leaking prosthetic           | 3                             | 1.9      | 3                             | 2.7      | 0.073          |
| Prosthetics removal (other than infection) | 6                              | 3.9     | 5                             | 4.5      | 1.000          |
| Infection (requiring prosthetics removal) | 5                               | 3.2     | 6                             | 5.4      | 0.535          |
| Seroma (breast)                       | 7                             | 4.5      | 0                             | 0.0      | 0.044          |
| Hematoma (breast)                     | 0                             | 0.0      | 3                             | 5.4      | 0.766          |
| Scar revision                         | 6                             | 3.9      | 6                             | 5.4      | 0.273          |
| Breast cellulitis                     | 3                             | 1.9      | 9                             | 8.0      | 0.032          |
| Skin necrosis                         | 12                            | 7.8      | 5                             | 4.5      | 0.319          |
| Fat necrosis                          | 0.6                           | 3        | 2.7                           | 0.313    |                |
| Follow-up period, mo                  | 33 (1, 191)                   | —        | 25 (1, 182)                   | —        | 0.100          |

### Table 7. ADM (Breasts) Complications Based on Radiation Therapy

| Variable                              | Without Radiotherapy (n = 190) | Rate (%) | With Radiotherapy (n = 28) | Rate (%) | P (Two-tailed) |
|---------------------------------------|-------------------------------|----------|----------------------------|----------|----------------|
| Age at first stage, y                 | 55 (23, 84)                   | 55 (37, 71) | —                             | 28.6     | 0.467          |
| Unplanned Reoperation                 | 41                            | 21.6     | 8                             | 7.1      | 1.000          |
| Malposition                           | 12                            | 6.3      | 2                             | 7.1      | 0.292          |
| Capsular contracture (grade III/IV)   | 4                             | 2.1      | 6                             | 21.4     | <0.001         |
| Time of onset of capsular contracture, mo | 11 (6, 30)                 | 14 (10, 19) | —                             | 0.5      |                |
| Ruptured/leaking prosthetic           | 1                             | 0.5      | 1                             | 3.6      | 0.241          |
| Prosthetic removal (other than infection) | 5                               | 2.6     | 2                             | 7.1      | 0.001          |
| Infection (requiring prosthetic removal) | 11                              | 5.8     | 1                             | 3.6      | 1.000          |
| Seroma (breast)                       | 6                             | 3.2      | 2                             | 7.1      | 0.600          |
| Hematoma (breast)                     | 2                             | 1.1      | 2                             | 7.1      | 0.081          |
| Scar revision                         | 12                            | 6.3      | 2                             | 7.1      | 1.000          |
| Breast cellulitis                     | 7                             | 3.7      | 2                             | 7.1      | 0.608          |
| Skin necrosis                         | 11                            | 5.8      | 4                             | 14.3     | 0.109          |
| Fat necrosis                          | 3                             | 1.6      | 1                             | 3.6      | 1.000          |
| Follow-up period, mo                  | 17 (1, 76)                    | —        | 19 (7, 54)                    | —        | 0.16           |
described a suboptimal aesthetic profile for LDMF, and others claim the inframammary fold has a better cosmetic outcome with ADM.30,32,37 However, LDMF does offer increased volume secondary to the thickness of the muscle, subcutaneous tissue, plus the skin paddle if fashioned for the flap.22 Although muscle atrophy can decrease final volume, this can be adjusted with fat grafting.32,39–41

In breast reconstruction, quality of life outcomes are crucial factors. This study used BREAST-Q, a widely validated tool, to assess the impact on quality of life.38 There is still debate about which technique is superior, and some important factors must be considered when determining the optimal approach. For example, LDMF has been associated with postoperative shoulder weakness, donor site morbidity and is relatively contraindicated in patients with a history of posterolateral thoracotomy.34,42,43 ADM has been determined superior to LDMF regarding hospital resource utilization with fewer readmissions and shorter lengths of stay.47 This advantage is especially noted when ADM is performed as a single stage procedure, with direct to implant placement.22,47,48 Although ADM is expensive, usually costing $2,000–$5,000 per patient, it takes 79–165 minutes less operating room time compared with LDMF.21,22,29,47 Further, ADM has been determined superior to LDMF by the Radiation Oncology Department.22,25,47 This desirable feature of the LDMF over ADM could be a deciding factor for which reconstruction modality to choose, especially in more advanced cancer patients who need radiotherapy.

There are no significant differences in BREAST-Q scores between either cohort.

Breast cancer treatment is a multidisciplinary approach and radiotherapy is a pivotal component to consider when planning reconstruction. We found a higher incidence of patients receiving LDMF in those who had a history of radiotherapy. LDMF is typically preferred in patients with radiotherapy because it inserts vascularized tissue coverage in ischemic postirradiation chests.32 The flap can also be performed as a delayed or salvage procedure to reduce radiation-associated complications.30,32,37,42 This is a potential advantage over ADM, which relies on incorporation and neovascularization. We also noticed that patients with ADM who received radiotherapy had higher rates of capsular contracture compared with LDMF patients with radiotherapy (21% versus 3.6%). This contrasts previous literature that ADM decreases capsular contracture rates, even in the presence of radiotherapy.34–36 This desirable feature of the LDMF over ADM could be a deciding factor for which reconstruction modality to choose, especially in more advanced cancer patients who need radiotherapy.

### Table 8. Summary and Association of Breast-Q Satisfaction Scores for LDMF with Radiation Versus LDMF without Radiation Patients

| Score Variables          | Overall Sample (N = 58) | Without Radiotherapy (N = 31) | With Radiotherapy (N = 27) |
|--------------------------|-------------------------|-------------------------------|---------------------------|
| Satisfaction with breasts | 71 (59, 91)             | 71 (59, 91)                   | 71 (55, 85)               |
| Satisfaction with outcome | 75 (61, 100)            | 75 (61, 100)                  | 75 (67, 75)               |
| Psycho-social well-being | 86 (70, 100)            | 82 (63, 100)                  | 92 (76, 100)              |
| Physical well-being      | 63 (49, 77)             | 60 (47, 77)                   | 63 (49, 85)               |
| Satisfaction with nipples | 83 (74, 100)            | 88 (77, 100)                  | 81 (74, 100)              |
| Satisfaction with information | 55 (31, 89)      | 61 (36, 100)                  | 41 (31, 81)               |
| Satisfaction with information | 80 (64, 100)    | 77 (62, 100)                  | 85 (64, 100)              |

The sample median (IQR) is given for continuous variables. The following variables have unavailable information: Satisfaction with outcome (n = 7), physical well-being: chest (n = 6), satisfaction with nipples (n = 25), surgeon (n = 4), and office staff (n = 2).

### Table 9. Summary and Association of Breast-Q Satisfaction Scores for ADM with Radiation Versus ADM without Radiation Patients

| Score Variables          | Overall Sample (N = 20) | Without Radiotherapy (N = 14) | With Radiotherapy (N = 6) |
|--------------------------|-------------------------|-------------------------------|---------------------------|
| Satisfaction with breasts | 66 (59, 82)             | 71 (61, 91)                   | 61 (58, 64)               |
| Satisfaction with outcome | 75 (64, 93)             | 75 (67, 86)                   | 75 (47, 100)              |
| Psycho-social well-being | 84 (63, 100)            | 92 (82, 100)                  | 68 (55, 79)               |
| Physical well-being      | 63 (38, 77)             | 68 (47, 77)                   | 42 (37, 63)               |
| Satisfaction with nipples | 85 (71, 91)             | 85 (73, 91)                   | 73 (55, 93)               |
| Satisfaction with information | 61 (50, 100)    | 61 (61, 81)                   | 68 (36, 100)              |
| Satisfaction with information | 88 (70, 100)    | 96 (77, 100)                  | 70 (54, 91)               |
| Surgeon                  | 100 (100, 100)          | 100 (100, 100)                | 100 (81, 100)             |
| Medical staff            | 100 (100, 100)          | 100 (100, 100)                | 100 (91, 100)             |
| Office staff             | 100 (100, 100)          | 100 (100, 100)                | 100 (100, 100)            |

The sample median (IQR) is given for continuous variables. The P values were obtained using Wilcoxon rank sum exact test. The following variables have unavailable information: satisfaction with outcome (n = 4), physical well-being: chest (n = 3), satisfaction with nipples (n = 13), surgeon (n = 3), and office staff (n = 1).

IQR, inter-quartile range.
Regarding future directions, a cost analysis is needed to determine the exact difference in resource utilization between the 2 procedures. The current literature is also lacking in data directly comparing ADM with other breast reconstructive techniques.

Our study is not foreign to limitations. Due to the retrospective nature of our work, there is a potential for recall bias and confounding. Besides, as a retrospective chart review, the impact of our findings is inferior to a prospective study. Furthermore, 3 different surgeons performed the reconstructive procedures analyzed in this study. Additionally, the Breast-Q™ had a low response rate (21.3%) and is not fully structutive procedures analyzed in this study. Additionally, the Breast-Q™ had a low response rate (21.3%) and is not fully representative of our patient population. Also, skin paddles were used in some LDMF patients, which can create a different aesthetic appearance compared with not using skin islands. Finally, the LDMF cohort had a significantly higher rate of prior radiotherapy. This demographic difference could impact outcome comparisons between these 2 groups.

CONCLUSIONS

When comparing ADM to LDMF in EBR, there were no significant differences in postoperative complications or aesthetic outcomes. This study supports that ADM performs as well as LDMF in EBR and both modalities are comparable alternatives for breast reconstruction after mastectomy. Notably, however in patients with a history of radiotherapy, there was a higher capsular contracture rate when using ADM.

J. Randall Patrinely, Jr, BA
Vanderbilt University School of Medicine
200 21st Ave S
Nashville, TN 37203
E-mail: james.r.patrinely@vanderbilt.edu

REFERENCES

1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17:43–46.
2. Tover LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25:16–27.
3. Tao Z, Shi A, Lu C, et al. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–338.
4. 2017 Cosmetic Plastic Surgery Statistics. 2017 Cosmetic Plastic Surgery Statistics, American Society of Plastic Surgeons, 2017.
5. Larson DL, Anderson RC, Maksud D, et al. What influences public perceptions of silicone breast implants? Plast Reconstr Surg. 1994;94:318–325; discussion 326.
6. Palcheff-Wiener M, Concannon MJ, Conn VS, et al. The impact of the media on women with breast implants. Plast Reconstr Surg. 1993;92:779–785.
7. Schneider WJ, Hill HL, Jr, Brown RG. Latissimus dorsi myocutaneous flap for breast reconstruction. Br J Plast Surg. 1977;30:277–281.
8. Oliviari N. Use of thirty latissimus dorsi flaps. Plast Reconstr Surg. 1979;64:654–661.
9. Bostwick J 3rd, Nahai F, Wallace JG, et al. Sixty latissimus dorsi flaps. Plast Reconstr Surg. 1979;63:31–41.
10. Abdalla HM, Shalaan MA, Fouad FA, et al. Immediate breast reconstruction with expander assisted latissimus dorsi flap after skin sparing mastectomy. J Egypt Natl Canc Inst. 2006;18:134–140.
11. Mast BA, Simonneau DK. Latissimus dorsi breast reconstruction utilizing functional muscle transfer and tissue expansion. Ann Plast Surg. 2006;56:379–384.
12. Erikssen C, Stark B. The latissimus dorsi flap—still a valuable tool in breast reconstruction: report of 32 cases. Scand J Plast Reconstr Hand Surg. 2008;42:132–137.
13. Bostwick J 3rd, Scheffan M, Nahai F, et al. The “reverse” latissimus dorsi muscle and musculocutaneous flap: anatomical and clinical considerations. Plast Reconstr Surg. 1980;65:395–399.
14. Olivari N. The latissimus flap. Br J Plast Surg. 1976;29:126–128.
15. Sternberg EG, Perdikis G, McLaughlin SA, et al. Latissimus dorsi flap remains an excellent choice for breast reconstruction. Ann Plast Surg. 2006;56:31–35.
16. Freeman ME, Perdikis G, Sternberg EG, et al. Latissimus dorsi reconstruction: a good option for patients with failed breast conservation therapy. Ann Plast Surg. 2006;57:134–137.
17. Duncan DI. Correction of implant rippling using allograft dermis. Aesthet Surg J. 2001;21:81–84.
18. Bindingnavele V, Gaoon M, Ota KS, et al. Use of acellular cadaveric dermis and tissue expansion in postmastectomy breast reconstruction. J Plast Reconstr Aesthet Surg. 2007;60:1214–1218.
19. Woo RJ, Park JW, Mun GH, et al. Does the use of acellular dermal matrix increase postoperative complications of the first-stage reconstruction of immediate expander-implant breast reconstruction: a matched cohort study. Ann Plast Surg. 2017;79:341–345.
20. Forsberg CG, Kelly DA, Wood BC, et al. Aesthetic outcomes of acellular dermal matrix in tissue expander/implant-based breast reconstruction. Ann Plast Surg. 2014;72:5116–5120.
21. de Blacam C, Momoh AO, Colakoglu S, et al. Cost analysis of implant-based breast reconstruction with acellular dermal matrix. Ann Plast Surg. 2012;69:516–520.
22. Johnson RK, Wright CK, Gandhi A, et al. Cost minimisation analysis of using acellular dermal matrix (strattice™) for breast reconstruction compared with standard techniques. Eur J Surg Oncol. 2013;39:242–247.
23. Berlin NL, Hamill JB, Qi J, et al. Nonresponse bias in survey research: lessons from a prospective study of breast reconstruction. J Surg Res. 2018;224:112–120.
24. Chun YS, Verma K, Rosen H, et al. Implanted-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications. Plast Reconstr Surg. 2010;125:429–436.
25. Liu AS, Kao HK, Reish RG, et al. Postoperative complications in prophylactic breast reconstruction using acellular dermal matrix. Plast Reconstr Surg. 2011;127:1755–1762.
26. Preminger BA, McCarthy CM, Hu QY, et al. The influence of allograft on expander dynamics and complications in the setting of immediate tissue expander/implant reconstruction: a matched-cohort study. Ann Plast Surg. 2008;60:510–513.
27. De Mey A, Lejour M, Decleey E, et al. Late results and current indications of latissimus dorsi breast reconstructions. Br J Plast Surg. 1991;44:1–4.
28. Kankam HKN, Hourston GJM, Fopp LJ, et al. Trends in post-mastectomy breast reconstruction types at a breast cancer tertiary referral centre before and after introduction of acellular dermal matrices. J Plast Reconstr Aesthet Surg. 2018;71:21–27.
29. Youassel MM, Pucher PH, Kennedy K, et al. Use of acellular dermal matrix versus latissimus dorsi flap for breast reconstruction: clinical and patient-reported outcomes. Br J Surg. 2016;22:702–704.
30. DeLong MR, Tandon VJ, Rudkin GH, et al. Latissimus dorsi flap breast reconstruction—A nationwide inpatient sample review. Ann Plast Surg. 2017;78(4 Suppl 1):S185–S188.
31. Ho G, Nguyen TJ, Shahabi A, et al. A systematic review and meta-analysis of complications associated with acellular dermal matrix-assisted breast reconstruction. Ann Plast Surg. 2012;68:346–356.
32. Feng J, Pardoe CI, Mota AM, et al. Two-stage latissimus dorsi flap with implant for unilateral breast reconstruction: getting the size right. *Arch Plast Surg.* 2016;43:197–203.

33. Cook J, Waughtel J, Brooks C, et al. The muscle-sparing latissimus dorsi flap for breast reconstruction: a retrospective review of 126 consecutive flaps. *Ann Plast Surg.* 2017;78(6 Suppl 5):S263–S268.

34. Sood R, Easow JM, Konopka G, et al. Latissimus dorsi flap in breast reconstruction: recent innovations in the workhorse flap. *Cancer Control.* 2018;25:1073274817744638.

35. Perdikis G, Koonce S, Collis G, et al. Latissimus dorsi myocutaneous flap for breast reconstruction: bad rap or good flap? *Eplasty.* 2011;11:e39.

36. Cai R, Xie Z, Zhou L, et al. Pedicled descending branch latissimus dorsi mini-flap for repairing partial mastectomy defect: a new technique. *Plast Reconstr Surg Glob Open.* 2018;6:e1692.

37. Fracol M, Grim M, Lanier ST, et al. Vertical skin paddle orientation for the latissimus dorsi flap in breast reconstruction: a modification to simultaneously correct inferior pole constriction and improve projection. *Plast Reconstr Surg.* 2018;141:598–601.

38. Cano SJ, Klassen AF, Scott AM, et al. The BREAST-Q: further validation in independent clinical samples. *Plast Reconstr Surg.* 2012;129:293–302.

39. Kazzazi F, Ching RC, Malata CM. Postmastectomy breast reconstruction with the totally autologous latissimus dorsi flap in the thin, small-breasted woman: give it more thought! *Eplasty.* 2018;18:e13.

40. Johns N, Fairbairn N, Trail M, et al. Autologous breast reconstruction using the immediately lipofilled extended latissimus dorsi flap. *J Plast Reconstr Aesthet Surg.* 2018;71:201–208.

41. Streit L, Dražan L, Schneiderová M, et al. Intraoperative fat grafting into the pectoralis and latissimus dorsi muscles: novel modification of autologous breast reconstruction with extended latissimus dorsi flap. *Acta Chir Plast.* 2017;59:72–81.

42. Garusi C, Manconi A, Lanni G, et al. Shoulder function after breast reconstruction with the latissimus dorsi flap: a prospective cohort study - combining DASH score and objective evaluation. *Brast.* 2016;27:78–86.

43. Eyjolfsdottir H, Haraldsdottir B, Ragnarsdottir M, et al. A prospective analysis on functional outcomes following extended latissimus dorsi flap breast reconstruction. *Scand J Surg.* 2017;106:152–157.

44. Kim IK, Park SO, Chang H, et al. Inhibition mechanism of acellular dermal matrix on capsule formation in expander-implant breast reconstruction after postmastectomy radiotherapy. *Ann Surg Oncol.* 2018;25:2270–2287.

45. Basu CB, Jeffers L. The role of acellular dermal matrices in capsular contracture: a review of the evidence. *Plast Reconstr Surg.* 2012;130(5 Suppl 2):118S–124S.

46. Hester TR Jr, Ghazi BH, Moyer HR, et al. Use of dermal matrix to prevent capsular contracture in aesthetic breast surgery. *Plast Reconstr Surg.* 2012;130(5 Suppl 2):126S–136S.

47. Kilchenmann AJ, Lardi AM, Ho-Asjoe M, et al. An evaluation of resource utilisation of single stage porcine acellular dermal matrix assisted breast reconstruction: a comparative study. *Brast.* 2014;23:876–882.

48. Losken A, Nicholas CS, Pinell XA, et al. Outcomes evaluation following bilateral breast reconstruction using latissimus dorsi myocutaneous flaps. *Ann Plast Surg.* 2010;65:17–22.